Baptist Health South Florida

Scholarly Commons @ Baptist Health South Florida
All Publications
2021

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia
endpoints in heart failure with reduced ejection fraction
Sandra Chaparro
Baptist Health Medical Group; Miami Cardiac & Vascular Institute, SandraCh@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications

Citation
Heart Rhythm O2 (2021) 2(6Part B):724-732

This Article -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health
South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly
Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.

Sacubitril/valsartan versus angiotensin inhibitors and
arrhythmia endpoints in heart failure with reduced
ejection fraction
Amanda D.F. Fernandes, MD,* Gilson C. Fernandes, MD,† Caique M.P. Ternes,‡
Rhanderson Cardoso, MD,x Sandra V. Chaparro, MD,k
Jeffrey J. Goldberger, MD, MBA, FHRS†
From the *Department of Internal Medicine, University of Miami Miller School of Medicine, Miami, Florida,
†
Division of Cardiology, University of Miami Miller School of Medicine, Miami, Florida, ‡Cardiac
Arrhythmia Service, SOS Cardio Hospital, Florianopolis, Brazil, xDivision of Cardiology, Brigham and
Women’s Hospital, Boston, Massachusetts, and kMiami Cardiac and Vascular Institute, Baptist Health
South Florida, Miami, Florida.
BACKGROUND Angiotensin receptor–neprilysin inhibitor (ARNI)
therapy has been associated with improved survival for patients
with symptomatic heart failure and reduced ejection fraction
(HFrEF).
OBJECTIVES We performed a meta-analysis of arrhythmia endpoints from studies comparing ARNI with angiotensin-converting
enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)
for patients with HFrEF to assess for incremental beneﬁt.
METHODS We searched PubMed, Embase, and ClinicalTrials.gov.
Baseline study characteristics were collected and outcomes were
sustained ventricular arrhythmias, atrial arrhythmias, appropriate
implantable cardioverter-deﬁbrillator (ICD) therapy, sudden cardiac
death (SCD), and biventricular (BiV) pacing rate.
RESULTS We included 9 studies, 4 randomized trials, and 5 observational studies (5589 patients on ARNI vs 5615 on ACEIs/ARBs).
Follow-up ranged from 2 to 51 months. The mean age was 65.4 6
9.8 years, with 77.3% male patients and a mean ejection fraction
of 29.0% 6 7.6%. Ischemic cardiomyopathy was present in 62%

Introduction
The underlying pathophysiology for arrhythmogenesis in patients with heart failure with reduced ejection fraction
(HFrEF) is complex and multifactorial, including ﬁbrosis,
neurohormonal imbalances, dysregulation of calcium homeostasis, endothelial factors, and alterations in the expression of ion channels.1,2
Sacubitril/valsartan, an angiotensin receptor–
neprilysin inhibitor (ARNI), has been broadly recommended for patients with HFrEF since the survival beneﬁt
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of patients. In the ARNI group, there were less SCD (odds ratio
[OR] 0.78, 95% conﬁdence interval [CI] 0.63–0.96; P 5 .02), ventricular arrhythmias (OR 0.45, 95% CI 0.25–0.79; P 5 .005), and
appropriate ICD therapy (OR 0.39, 95% CI 0.21–0.74; P 5 .004).
Higher rates of BiV pacing were seen (mean difference 3.13, 95%
CI 2.58–3.68; P , .00001) when compared with ACEIs/ARBs. No
difference in atrial arrhythmias was seen.
CONCLUSION ARNI therapy provides incremental beneﬁt with
respect to ventricular tachyarrhythmias/SCD, which may, in part,
explain improved outcomes in patients with HFrEF compared to
ACEIs/ARBs. There was increased BiV pacing and decreased ICD
therapy in the ARNI group.
KEYWORDS Angiotensin receptor antagonists; Antiarrhythmia
agents; Heart failure; Sacubitril-valsartan; Sudden cardiac death
(Heart Rhythm O2 2021;2:724–732) © 2021 Heart Rhythm Society.
Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).

demonstrated in the PARADIGM-HF trial. 3 The latest
2021 update to the 2017 American College of Cardiology
Expert Consensus Decision Pathway for Optimization of
Heart Failure Treatment recommends the use of ARNI
rather than angiotensin-converting enzyme inhibitors
(ACEIs) or angiotensin receptor blockers (ARBs) as
a class I recommendation in addition to beta blockers,
aldosterone antagonists, and sodium-glucose cotransporter-2 inhibitors in patients with HFrEF, unless contraindicated.4 A recent meta-analysis including 20 studies
and 10,175 patients demonstrated improvement in cardiac reverse remodeling with ARNI compared with
ACEIs/ARBs for both ischemic and nonischemic cardiomyopathy, at 3-month follow-up and with even more pronounced effect at 12 months. 5

2666-5018/© 2021 Heart Rhythm Society. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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KEY FINDINGS
-

Angiotensin receptor–neprilysin inhibitor (ARNI) use
in patients with heart failure and reduced ejection fraction was associated with a lower incidence of sudden
cardiac death and ventricular arrhythmias and lower
rates of appropriate deﬁbrillator shocks.

-

Biventricular (BiV) pacing percentage is inversely proportional to ventricular arrhythmias and a subanalysis
of observational studies demonstrated higher BiV pacing rates in the group treated with ARNI.

-

The role of ARNI as a potential antiarrhythmic should
be further explored and the modulation of the calcium
homeostasis might be one of the novel therapeutic targets of heart failure treatment.

Given the impact of remodeling in the pathophysiology of
arrhythmia generation, we aimed to study the role of ARNI
compared with ACEIs/ARBs in arrhythmia prevention for
patients with HFrEF.

Methods
Search strategy
This study followed the recommendations of the Preferred
Reporting Items for Systematic Reviews and Meta-analysis
(PRISMA)
protocol.
MEDLINE
(via
PubMed),
ClinicalTrials.gov, Embase, and Scopus were systematically
searched using the following strategy: (“sacubitril valsartan
sodium hydrate” [text word] OR “sacubitril valsartan drug
combination” [text word] OR “entresto” [tiab] OR “sacubitril-valsartan” [tiab] OR “LCZ696” [supplementary
concept] OR “Angiotensin Receptor-Neprilysin Inhibitor”
[text word]) AND (heart failure) NOT “preserved ejection
fraction” [tiab]). The search strategy was performed by 2 authors (AF and GCF) on March 22, 2020.

Eligibility criteria and data extraction
Studies with the following characteristics were included: (1)
adult patients .18 years old with diagnosed HFrEF; (2) randomized controlled trials (RCTs) or crossover or observational cohort studies; (3) at least 1 arm with use of ARNI;
(4) presence of an active control group with use of ACEIs/
ARBs; (5) reported incidence of arrhythmic endpoints either
in manuscript or at clinicaltrials.gov. There was no restriction
with respect to date of publication, publication status, or language.
Studies with no report of arrhythmic endpoints or duplicate data (published by the same authors or same institution
in an overlapping period) were excluded. In cases of duplicate data, only the study with the larger number of patients
that contained the variables of interest was selected. All
data were reviewed by the senior author (JJG).
All the studies that were deemed appropriate by the eligibility criteria had initially the full text analyzed followed by
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their supplementary material and the results section on
ClinicalTrials.gov in order to access the arrhythmic endpoints of interest.

Variables of interest
Controlled studies commonly report serious adverse events
according to the Medical Dictionary for Drug Regulatory Activities (MedDRAÒ) terminology, and its list of diagnoses
was reviewed to determine prespeciﬁed outcomes of interest
to be collected from the studies included.
Variables of interest were as follows: (1) study characteristics: study site and period, study design, sample size per
group, study population, and length of follow-up; (2) patient
characteristics: age, sex, race, mean ejection fraction (EF),
etiology of cardiomyopathy, medical therapy (beta blockers,
ACEIs/ARBs, mineralocorticoid receptor antagonists, and
antiarrhythmic therapy), frequency of implantable
cardioverter-deﬁbrillator (ICD) and cardiac resynchronization therapy (CRT); and (3) outcomes: incident ventricular
arrhythmias (ventricular tachycardia [VT] and/or ventricular
ﬁbrillation [VF]), incident atrial arrhythmias (atrial ﬁbrillation and/or atrial ﬂutter), composite of sudden cardiac death
(SCD), sudden death or cardiac arrest, appropriate ICD therapy (ICD shocks and/or antitachycardia pacing [ATP]
events), percentage of biventricular (BiV) pacing, and annualized rates of arrhythmia events.

Quality assessment and risk of bias
The quality of the included RCTs was assessed using the Cochrane Handbook of Systematic Reviews of Interventions6,7
and was presented as a risk of bias summary ﬁgure
(Supplemental Figure 1). For the nonrandomized studies,
we used the Newcastle-Ottawa scale8; the ﬁndings are presented in Supplemental Table 1.

Statistical analysis
Dichotomous endpoints were reported as frequencies and
continuous variables as mean 6 standard deviation if data
were normally distributed or median and interquartile range
for nonparametric data. Fixed-effects (FE) or randomeffects (RE) models were used to estimate the intervention effects. Outcomes from randomized trials were analyzed using
an FE model given the homogeneous inclusion criteria, populations, and methods across studies while RE model was
used for observational studies. Heterogeneity was also evaluated with I2 statistics and I2 . 20% was considered as high
heterogeneity; RE statistics were also used in those cases.
Sensitivity analysis was performed to identify possible outliers, and if an obvious reason for the outlying result could
be identiﬁed this study was removed from the analysis.6,7 Binary endpoint treatment effects were compared using pooled
odds ratio (OR) with a 95% conﬁdence interval (CI), and
continuous variables were compared using mean difference
and a 95% CI. Review Manager 5.3 was used for statistical
analysis (The Nordic Cochrane Centre, The Cochrane
Collaboration, Denmark, Copenhagen).
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Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) ﬂow diagram. ACEi 5 angiotensin-converting enzyme inhibitor;
ARB 5 angiotensin receptor blocker.

Cumulative incidence of events was estimated by dividing
the total number of events for each variable by the number of
patient-years included in the analysis and was presented as
events per 1000 patient-years.

achieved in 4 out of 5 studies that reported these data and
the frequency of guideline-directed medical therapy
(GDMT) at the time of recruitment is speciﬁed in
Supplemental Table 2.

Results

Arrhythmia endpoints

Baseline characteristics

Funnel plot analysis determined that results from ElBattrawy and colleagues13 were outliers in the analyses for
the variables ventricular arrhythmias and ICD therapy
(appropriate ICD shocks and/or ATP therapy), and sensitivity
analysis conﬁrmed that the exclusion of this study led to signiﬁcant reduction in heterogeneity. Furthermore, quality
assessment determined high risk of bias for this study owing
to the retrospective model associated with a 53% loss of
follow-up from the original sample (Supplemental Figure 2
and Supplemental Table 1). Therefore, that study was
excluded from these analyses.

A total of 4 RCTs3,9–11 and 5 observational studies12–16
published between 2018 and 2020 met the inclusion criteria
(Figure 1, Table 1), representing a total of 11,204 patients,
of whom 5589 were in the ARNI group (49.9%) and 5615
in the ACEIs/ARBs group (50.1%). Mean age was 65.4 6
9.8 years, with a majority male (77.3%). All included patients
had an EF 40%, with a mean EF of 29.0% 6 7.6%. Six
studies reported the etiology of the cardiomyopathy,10,12–16
which was ischemic in 62%. Follow-up ranged from 2 to
51 months (Table 2). The maximum dose of ARNI was
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Table 1 Characteristics of included studies with patients with heart failure and reduced ejection fraction treated with angiotensin receptor–
neprilysin inhibitor vs angiotensin inhibitors (angiotensin-converting enzyme inhibitors / angiotensin receptor blockers)

Study (year)
Randomized
controlled
trials
EVALUATE-HF
(2019)
OUTSTEP-HF
(2018)
PARADIGM-HF
(2019)
PIONEER-HF
(2020)

NCT number

Population

EF 40%

1:1

231/233

3

Chronic HF (EF
1:1
40%), class II
EF 35%
1:1

309/310

3

4209/4233

51

EF 40%, stabilized 1:1
post
hospitalization for
acute
decompensated HF

443/444

2

Observational
EF 40%, class II, NA
prospective cohort and ICD
Retrospective cohort EF 40%, class II, NA
presence of ICD,
CRT, pacemaker
and/or loop
recorder
Prospective cohort EF 40%, class II NA

120/120

18

127/127

12

35/35

6

Retrospective cohort EF ,35%, class II–IV, NA
presence of ICD or
CRT and prior ACEI/
ARB treatment
Observational
EF 35% and ICD
NA
prospective cohort

151/151

12

42/42

24

Study design

NCT02874794 85 US sites

Randomized, doubleblind
NCT02900378 Multicenter (127
Randomized, doublesites)
blind
Randomized, parallel
NCT01035255 Multicenter (1030
assignment,
sites at US, Latin
double-blind
America, Europe)
NCT02554890 Multicenter (127 US Randomized doublesites)
blind, double
dummy, parallel
group, activecontrolled

Observational
studies
De Diego (2018) NA
El-Battrawy
(2019)

Location

N
intervention†/ Follow-up
(months)
Randomization control‡

Spain

NA

Germany

Valentim
NA
Gonçalves
(2019)
Martens (2019) NA

Portugal

Polymeropoulos NA
(2019)

Belgium

NA

ACEI 5 angiotensin-converting enzyme inhibitor; ARB 5 angiotensin receptor blocker; CRT 5 cardiac resynchronization therapy; EF 5 ejection fraction;
HF 5 heart failure; ICD 5 implantable cardioverter deﬁbrillator; NA 5 nonapplicable or nonavailable, NCT 5 National Clinical Trial.
†
Intervention: angiotensin receptor-neprilysin inhibitor.
‡
Control: angiotensin inhibitors (ACEIs/ARBs).

The composite outcome of SCD was available only for the
RCTs and it was statistically lower in the group treated with
ARNI when compared with ACEIs/ARBs (OR FE 0.78, 95%
CI 0.63–0.96; P 5 .02; Figure 2), although 96.5% of the
weight of this analysis was driven by the PARADIGM-HF
trial.3 There were 30 SCD events in the ARNI group (1.66/
1000 person-years) vs 62 SCD events for the ACEIs/ARBs
group (3.41/1000 person-years).
The rate of ventricular arrhythmias (VT and/or VF) in
patients receiving ARNI was statistically lower than
among those treated with ACEIs/ARBs (1.7% vs 2.4%;
OR FE 0.70, 95% CI 0.53–0.91; P 5 .008; Figure 3A)
when considering all studies. A total of 107 ventricular
arrhythmias were reported in patients treated with
ARNI (5.92/1000 person-years) when compared with
139 events on ACEIs/ARBs (7.65/1000 person-years).
If only RCTs were included in this analysis, there was
no statistical difference between groups (P 5 .15;
Figure 3B).

Data on BiV pacing were available only for the observational studies, and patients treated with ARNI had a higher
percentage of BiV pacing when compared with the ACEIs/
ARBs group (mean difference 3.13, 95% CI 2.32–3.95;
P , .00001; Figure 4). There was a lower rate of the composite outcome of appropriate ICD therapy (ICD shocks and/or
ATP) in the group treated with ARNI instead of ACEIs/
ARBs (16/313 vs 36/313, respectively; OR RE 0.41, 95%
CI 0.19–0.88; P 5 .02; Figure 5).
There was no difference in incidence of atrial arrhythmias
(atrial ﬁbrillation and/or ﬂutter) between ARNI and ACEIs/
ARBs groups (7.25/1000 person-years vs 7.59/1000
person-years; OR FE 1.01, 95% CI 0.78–1.30; P 5 .70;
Supplemental Figure 3).

Discussion
Our analysis demonstrates that patients with heart failure
(HF) and EF 40% treated with ARNI had a lower incidence
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Table 2

Baseline characteristics of included studies

Study (year)
Randomized
controlled
trials
EVALUATE-HF
(2019)
OUTSTEP-HF
(2018)
PARADIGM-HF
(2019)
PIONEER_HF
(2020)
Observational
studies
De Diego (2018)
El-Battrawy
(2019)
Valentim
Gonçalves
(2019)
Martens (2019)
Polymeropoulos
(2019)
TOTAL

Mean age 6 SD Male (%)

67.8 6 9.8

170 (74%)

White (%)

Mean EF

166 (72%)

34 6 10

137 (59%)

Aﬁb/VF/VT

NA

NA

NA

NA

NA

NA

NA

NA

Aﬁb/Aﬂutter/
VT/VF
Aﬁb/Aﬂutter/
VT/VF/SCD
Aﬁb/Aﬂutter/
VT/VF/SCD

NA

NA

56%/56%

44%/44%

67.16 6 11.04 238 (77%)

298
(96.4%)
63.78 6 11.52 3321 (78.9%) NA
61 (50.5, 71)x

69 6 8

327 (74.3%) 206 (60.2%) 24%
(18, 30)x
91 (76%)

66.8 6 12.1 NA

30.4% 6 4% 82%

NA

25% (5, 45)x 53%

Aﬁb/VF/VT/
ICD shocks/
BiV pacing
VT/VF

NA

15 (42.9%)

VT/SCD

85.6%/85.6% 20%/20%

29 6 9
NA

103 (69%)
68%

VT/VF
VT/ICD shocks

NA
100%/100%

51%
NA

29 6 7.6

62%

—

—

—

29 (82.9%) NA

67.7 6 9.9
67 6 9

123 (82%) NA
31 (73.8%) NA
77.3%

NA

14.9%/14.7% 7%/6.7%

NA

58.6 6 11.1

65.4 6 9.8

%CRT
%ICD
intervention†/ intervention†/
control‡
control‡

Ischemic
Outcomes of
cardiomyopathy interest

—

57.7%/64.2% 29%/35.5%

Aﬁb 5 atrial ﬁbrillation; Aﬂutter 5 atrial ﬂutter; BiV 5 biventricular; CRT 5 cardiac resynchronization therapy; EF 5 ejection fraction; ICD 5 implantable
cardioverter-deﬁbrillator; NA 5 nonapplicable or nonavailable; SCD 5 sudden cardiac death; SD 5 standard deviation; VF 5 ventricular ﬁbrillation; VT 5 ventricular tachycardia.
†
Intervention: angiotensin receptor–neprilysin inhibitor.
‡
Control: angiotensin inhibitors (angiotensin-converting enzyme inhibitors / angiotensin receptor blockers).
x
Median (interquartile range).

of SCD, ventricular arrhythmias, and appropriate ICD therapy and presented increased rates of BiV pacing when
compared with those on ACEIs/ARBs. There was not enough
evidence to support a difference in the incidence of atrial arrhythmias in patients treated with ARNI vs ACEIs/ARBs.
Caution is advised while interpreting the ventricular arrhythmias outcome given the absence of statistical difference
when only RCTs were included in the analysis. It is possible
that the smaller sample of patients recruited by the trials other
than the PARADIGM-HF as well as possible underreporting
of ventricular arrhythmia events could have been responsible

for the lack of a statistically signiﬁcant difference in this
outcome, and this should not discourage further research in
the ﬁeld. In addition, the favorable results of ARNI
increasing BiV pacing and decreasing appropriate ICD therapy demonstrated by the observational studies need subsequent investigation, given the lower quality of the studies.
A detailed review of the mechanisms of action that are
potentially implicated in the antiarrhythmic effects of
ARNI points towards its modulatory simultaneous effect on
the calcium homeostasis and in 2 of the major neurohormonal
regulatory systems: the renin-angiotensin-aldosterone

Figure 2 Composite outcome of sudden cardiac death, cardiac arrest, and sudden death among patients treated with angiotensin receptor–neprilysin inhibitor
(ARNI) vs angiotensin inhibitors (angiotensin-converting enzyme inhibitors [ACEIs] / angiotensin receptor blockers [ARBs]) in randomized studies.
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Figure 3 Ventricular arrhythmias among patients treated with angiotensin receptor–neprilysin inhibitor (ARNI) vs angiotensin inhibitors (angiotensin-converting enzyme inhibitors [ACEIs] / angiotensin receptor blockers [ARBs]) including all studies (A) and only on randomized controlled trials (B).

system and the natriuretic peptide system, which are overactivated in patients with advanced HF (graphical abstract).1,17,18 The inhibition of the angiotensin receptor and
the neprilysin (a zinc metalloprotease present in the endothelial surface of multiple organ systems) results in modulation
of the renin-angiotensin-aldosterone system and natriuretic
peptide system. Neprilysin inhibition increases the levels of
multiple peptides associated with peripheral vasodilation
(natriuretic peptides, bradykinin, substance P, adrenomedullin), increasing glomerular ﬁltration rate with subsequent
diuresis and natriuresis (atrial natriuretic peptide effect).17,19
Neprilysin inhibition also decreases cardiomyocyte hypertrophy by promoting increased levels of atrial natriuretic peptide
and brain natriuretic peptide, which inhibit the angiotensin II
and endothelin 1 that are responsible for cardiomyocyte and
ﬁbroblast growth.20 With HF progression, both mechanical
and electrical remodeling are observed in the cardiomyocytes. In a normal heart, the action potential depolarizes the
L-type calcium channels at the T-tubules, promoting calcium
entrance. The calcium is sensed by the ryanodine receptor
type 2 (RyR2) on the surface of the sarcoplasmic reticulum
(SR) and causes its opening, resulting in the efﬂux of accumulated calcium to the intracellular space. Calcium
binds to the actin and its conformational change promotes

the myocardial contraction (systole).21 Excessive cytosolic
calcium either enters back into the SR through the SR
Ca21-ATPase-2a or is pumped out the cell in exchange for
sodium by the sodium and calcium exchanger during diastole, which results in the cell relaxation. RyR2 malfunction
owing to conformational changes secondary to HF progression and oxidative stress causes diastolic calcium leak that
is known to cause ventricular arrhythmias by delayed afterdepolarizations.1,21,22 ARNI seems to decrease the diastolic calcium leak from the SR.23 The calcium/calmodulin-dependent
protein kinase II plays a crucial role on the sodium and calcium homeostasis and it is also damaged during oxidative
stress, resulting in arrhythmias because of early afterdepolarizations, prolongation of action potential, and delayed afterdepolarizations. Hemodynamic improvement promoted by
ARNI results in less oxidative stress and fewer translational
modiﬁcations in the intracellular ion channels involved in
calcium homeostasis, which may be the mechanism implicated in the reduction of malignant arrhythmias and sudden
cardiac death (graphical abstract).1,17,18,21
Prior studies demonstrated that intracellular diastolic calcium leak secondary to RyR2 malfunction or calcium/
calmodulin-dependent protein kinase II overactivation resulting from oxidative stress in failing hearts are associated with

Figure 4 Percentage of biventricular pacing among patients treated with angiotensin receptor–neprilysin inhibitor (ARNI) vs angiotensin inhibitors (angiotensin-converting enzyme inhibitors [ACEIs] / angiotensin receptor blockers [ARBs]) in observational studies.
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Figure 5 Composite outcome of appropriate implantable cardioverter deﬁbrillator (ICD) shocks and/or antitachycardia pacing in patients treated with angiotensin receptor–neprilysin inhibitor (ARNI) vs angiotensin inhibitors (angiotensin-converting enzyme inhibitors [ACEIs] / angiotensin receptor blockers [ARBs])
in observational studies.

ventricular arrhythmias and SCD.24–27 An experimental
study with murine and human cardiomyocytes models of
end-stage HF aimed to test the effect of ARNI vs valsartan
only in calcium homeostasis observed that under normal conditions there was no change in diastolic Ca21-spark frequency or SR Ca21 leak regardless of the therapy given;
however, under catecholamine stress, there was a 50% and
74% decrease in those 2 parameters of Ca21 diastolic leak
(P , .01) on murine and human cardiomyocytes treated
with ARNI, respectively, while there was no change in the
valsartan group.23
Additional mechanisms of action of ARNI are related to
its effects on vasodilation, natriuresis, decrease in sympathetic activation, decrease in wall stretch and myocardial
ﬁbrosis (graphical abstract), and reduced inﬂammation in human and animal models.14,19,28,29 Valentim Gonçalves and
colleagues14 prospectively studied patients with chronic HF
(NYHA class III) on optimal GDMT for at least 6 months
(100% on beta blockers, 94.3% on mineralocorticoid receptor antagonist, 85.6% with ICD, and 20% with CRT) and
recently started on ARNI and found a decrease in QRS duration and QTc interval, decrease in global longitudinal strain,
and mechanical dispersion index by echocardiography after 6
months of therapy. Although the ACEIs are known to promote reverse remodeling, they have not been implicated in
SCD reduction and the neprilysin inhibition could be a potential key for the observed 20% reduction in cardiovascular
death (including sudden death and death due to worsening
HF) observed by the PARADIGM-HF trial in patients treated
with ARNI when compared with enalapril.3,30,31
Scar and ﬁbrosis are important predictors of VT/VF, SCD,
and appropriate ICD therapy.32 The presence of myocardial
scar is known to create a reentrant substrate for VT/VF, as
the electrophysiologic heterogeneity created by the ﬁbrosis
interspersed with normal myocardium promotes slow
conduction and dispersion of repolarization/refractoriness.1,2
Myocardial ﬁbrosis is commonly observed in patients with
chronic HF secondary to an imbalance between production
and degradation of extracellular matrix as a result of neurohormonal, metabolic and hemodynamic dysregulation.5
Zile and colleagues33 recruited 2067 participants from the
PARADIGM-HF trial3 and tested 8 different biomarkers
before and after ARNI initiation, observing a decrease in proﬁbrotic markers 8 months after randomization (2 of them
associated with change in outcomes), and a decrease in
myocardial ﬁbrosis may be one of the factors to explain the

lower rates of SCD and ventricular arrhythmias in patients
treated with ARNI compared with ACEIs/ARBs observed
in our study.
We decided to include in our outcomes the BiV pacing
rates based on a literature review that points towards lower
rates of ventricular arrhythmias in patients that experienced
improvement in dyssynchrony. Kutyifa and colleagues,34 in
a subanalysis of the MADIT-CRT trial, compared the ﬁrst
episode of VT/VF/death in 764 patients with baseline left
bundle branch block and found that an improvement in dyssynchrony of at least 15% promoted by CRT-D was associated with a statistically signiﬁcant reduction of ventricular
arrhythmias at 12 months of follow-up. Hayes and colleagues35 analyzed mortality per quartile of BiV pacing percentage (,95%, 95%–98.5%, 98.5%–99.6%, .99.6%) in a
large cohort of 36,935 patients, and reported that a BiV pacing percentage above 99.6% was associated with a 24%
reduction in overall mortality when compared with other
quartile groups and patients with ,95% BiV pacing percentage had a 19% increase in mortality, concluding that even
small increases in the % BiV pacing were clinically relevant.
Our study showed an increase in the BiV pacing rate and a
decrease in appropriate ICD shocks and/or ATP therapy for
patients receiving ARNI in a subanalysis composed by observational studies. These ﬁndings are in accordance with a
recently published expert opinion from the Heart Rhythm
and Heart Failure sections of the Polish Cardiac Society,36
which defends that optimization of medical therapy in HF
with ARNI might have the additional beneﬁt of decreasing
the incidence of appropriate and inappropriate ICD shocks
and to increase the rate of BiV pacing. There are no trials reporting BiV pacing rates in patients treated with ARNI and
our meta-analysis provides the most updated evidence of
this beneﬁt. One of the included studies12 found that patients
with high premature ventricular contraction burden had a
lower percentage of BiV pacing rate and patients treated
with ARNI achieved reduction of premature ventricular
contraction burden and, subsequently, increase in BiV pacing
from 95% 6 6% to 98.8% 6 1.3% at 9 months, which could
represent another potential explanation for the higher rates of
BiV pacing in the ARNI group.
Despite the lower risk of SCD in patients with HFrEF who
had ICD implantation, ICD shocks have been linked to
increased risk of mortality.1 Proietti and colleagues37 reported an increase in cardiac deaths for patients receiving
both appropriate and inappropriate ICD shocks, with a higher
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effect size for appropriate therapy (hazard ratio 2.95, 95% CI
2.12, 4.11). There is still debate as to whether the relationship
between ICD shocks and mortality is either a result of the HF
progression itself or owing to myocardial injury/stunning
caused by the electrical current, or both.38 Powell and colleagues39 studied patients with ICD who received therapy
(appropriate or inappropriate) in order to determine if the
increased mortality after shock was due to the triggering
rhythm or secondary to the shock itself, and they concluded
that the presenting rhythm was the major factor impacting
prognosis, and shocks for VT/VF, atrial ﬁbrillation, or atrial
ﬂutter were associated with a higher risk of death when
compared with controls without shocks or with inappropriate
shocks due to noise, oversensing, or artifact. Lastly, Aktaş
and colleagues40 in a cohort including 5516 patients enrolled
in 5 landmark ICD trials observed that only appropriate ICD
shocks were associated with a 38% increased mortality risk at
3 years of follow-up when compared with inappropriate ICD
shocks, and mortality was higher in patients who experienced
fast VT (200 beats/min) or VF compared with patients
without fast VT or VF (27% vs 10%, respectively). Our analysis of observational studies did show a decrease in appropriate ICD shocks and/or ATP therapy for patients
receiving ARNI.

Limitations
The main limitations of our study include the small number of
trials and observational studies, the possible presence of
ascertainment bias, underreporting of arrhythmic events,
and the short and heterogenous length of follow-up in some
studies. In terms of ventricular arrhythmias, the studies did
not characterize the events in terms of sustained or not sustained, fast or slow events, and this information could potentially be helpful in subgroup analysis. Our analysis supports
the need for rigorous collection and adjudication of ventricular arrhythmia endpoints in modern HF trials. The main conclusions of the manuscript are derived from the
PARADIGM-HF trial.3 Regarding the use of GDMT, less
than 60% of patients enrolled by the PIONEER HF trial11
were on beta-blocker therapy and the presence of antiarrhythmic therapy was variable between the studies selected,
which could have inﬂuenced our results. Furthermore, no
studies reported the use of sodium-glucose cotransporter-2
inhibitors, which has been considered one of the modern cornerstones of GDMT for HFrEF patients, regardless of diabetic status, and has also been associated with decrease in
atrial arrhythmic events and SCD.41 Lastly, we advise
caution when interpreting the BiV pacing results, since this
variable was reported from device interrogation without analysis of BiV pacing morphology or unipolar electrograms to
conﬁrm true BiV pacing.

Conclusion
Our meta-analysis showed a signiﬁcant reduction in SCD
events, ventricular arrhythmias, and appropriate ICD therapy
in patients taking ARNI when compared with ACEIs/ARBs,
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as well as an increase in BiV pacing rate in patients with
HFrEF. We did not ﬁnd difference in atrial arrhythmic events
between groups. Caution is advised when interpreting those
results and, importantly, the observed associations do not
suggest a causal relationship between ARNI therapy and outcomes.
The neprilysin inhibition component and its effect on calcium homeostasis, decreased remodeling, and scar might be
intrinsically responsible for those ﬁndings and deserve
further investigation in dedicated trials and possibly in large
registries.
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